EGFR mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.
| Autor: | Muthusamy B; Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA., Berktas M; Global Oncology Outcome Research, AstraZeneca, Cambridge, UK., Li J; Global Medical Affairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA., Thomas DS; Global Oncology Outcome Research, AstraZeneca, Cambridge, UK., Sun P; Global Oncology Outcome Research, AstraZeneca, Cambridge, UK., Taylor A; Global Oncology Outcome Research, AstraZeneca, Cambridge, UK., Pennell NA; Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (28), pp. 2083-2096. Date of Electronic Publication: 2024 Jun 25. |
| DOI: | 10.1080/14796694.2024.2347826 |
| Abstrakt: | Aim: To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC). Methods: Electronic records of USA-based patients in the CancerLinQ Discovery ® database with stage IA-IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis. Results: Of 3121 (21.6%) patients who had EGFR testing, 493 (15.8%) were EGFR- mutation positive. Of 974 patients who underwent surgical resection, 513 (52.7%) received adjuvant therapy. A quarter of patients with EGFR- mutation positive NSCLC received targeted adjuvant therapy. Conclusion: Approximately a fifth of patients underwent EGFR testing; biomarker testing is important to ensure optimal outcomes for patients with stage I-III NSCLC. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|